Haploidentical Hematopoietic Stem Cell Transplantation for AML Patients with Persistent Molecular MRD

Abstract

Objective

The combined use of quantitative real-time polymerase chain reaction (qPCR) and next-generation sequencing (NGS) to detect molecular measurable residual disease (mMRD) has been shown to have prognostic value for patients undergoing matched-hematopoietic stem cell transplantation (HSCT). However, there have been no related studies in the context of haploidentical HSCT (haplo-HSCT).

Methods

We included 148 acute myeloid leukemia (AML) patients who were in first complete remission (CR1) and underwent HSCT at Union Hospital (Wuhan, China) between 2019 and 2023. Among them, 28 patients were mMRD (+) before transplantation according to PCR/NGS. Then, on the basis of the 2017 European Leukemia Net (ELN) risk stratification, we randomly enrolled 56 mMRD (–) patients at a 1:2 ratio. Finally, we compared the outcomes, including overall survival (OS), cumulative incidence of relapse (CIR), leukemia-free survival (LFS), and nonrelapse mortality (NRM), between the two groups.

Results

Persisting mMRD predicts worse long-term clinical outcomes in AML patients who received haplo-HSCT. The 2-year OS and LFS between the mMRD (+) and mMRD (–) groups were 77.1% (95%CI 62.5–95.2) versus 92.3% (95%CI 85.3–99.9) (P = 0.044) and 72.7% (95%CI 56.9–92.8) versus 90.7% (95%CI 83.2–98.8) (P = 0.003), respectively. The results of multivariate analysis revealed that mMRD (+) patients had worse OS and LFS than control patients did and that the mMRD (+) score was an independent prognostic factor for OS and LFS.

Conclusion

Pre-HSCT mMRD has predictive value for haplo-HSCT outcomes in AML patients. Patients who are mMRD (+) before transplantation have poorer OS and LFS. For these patients, intensified myeloablative conditioning (MAC), rapid reduction in immunosuppressive agents after 30 days, and pro-donor lymphocyte infusion (DLI) can improve post-transplant outcomes.

Keywords

Acute myeloid leukemia / Hematopoietic stem cell transplantation / Molecular measurable residual disease / Next-generation sequencing / Quantitative real-time polymerase chain reaction

References

[1] PapaemmanuilE, GerstungM, BullingerL, et al.. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med., 2016, 374(23): 2209-2221.

[2] DöhnerH, WeisdorfDJ, BloomfieldCD. Acute Myeloid Leukemia. N Engl J Med., 2015, 373(12): 1136-1152.

[3] ChafferCL, WeinbergRA. How does multistep tumorigenesis truly proceed?. Cancer Discov., 2015, 5(1): 22-24.

[4] LvM, WangY, ChangYJ, et al.. Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. Clin Cancer Res Off J Am Assoc Cancer Res., 2019, 25(6): 1737-1748.

[5] BejanyanN, WeisdorfDJ, LoganBR, et al.. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant., 2015, 21(3): 454-459.

[6] HouriganCS, GaleRP, GormleyNJ, OssenkoppeleGJ, WalterRB. Measurable residual disease testing in acute myeloid leukemia. Leukemia., 2017, 31(7): 1482-1490.

[7] DöhnerH, EsteyE, GrimwadeD, et al.. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood., 2017, 129(4): 424-447.

[8] IveyA, HillsRK, SimpsonMA, et al.. Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med., 2016, 374(5): 422-433.

[9] DöhnerH, WeiAH, AppelbaumFR, et al.. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood., 2022, 140(12): 1345-1377.

[10] HeuserM, FreemanSD, OssenkoppeleGJ, et al.. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood., 2021, 138(26): 2753-2767.

[11] WangL, ChenY, ZangM, et al.. Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a-rearranged acute myeloid leukemia. Cancer., 2025, 1312. e35717

[12] PastoreF, LevineRL. Next-Generation Sequencing and Detection of Minimal Residual Disease in Acute Myeloid Leukemia: Ready for Clinical Practice?. JAMA., 2015, 314(8): 778-780.

[13] DillonLW, GuiG, PageKM, et al.. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. JAMA., 2023, 329(9): 745-755.

[14] NaglerA, LabopinM, CraddockC, et al.. Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation. Am J Hematol., 2022, 97(3): 274-282.

[15] LiangEC, ChenC, LuR, MannisGN, MufflyL. Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation. Bone Marrow Transplant., 2021, 56(12): 3091-3093.

[16] KövyP, ŐrfiZ, BorsA, et al.. Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia. PLoS ONE., 2021, 166. e0253386

[17] MoariiM, PapaemmanuilE. Classification and risk assessment in AML: integrating cytogenetics and molecular profiling. Hematol Am Soc Hematol Educ Program., 2017, 2017(1): 37-44.

[18] TholF, GabdoullineR, LiebichA, et al.. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood., 2018, 132(16): 1703-1713.

[19] LeischM, JanskoB, ZaborskyN, GreilR, PleyerL. Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?. Cancers., 2019, 112252.

[20] HeuserM, HeidaB, BüttnerK, et al.. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Adv., 2021, 5(9): 2294-2304.

[21] KimHJ, KimY, KangD, et al.. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Blood Cancer J., 2021, 116109.

[22] LiY, Solis-RuizJ, YangF, et al.. NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia. Blood Cancer J., 2023, 13159.

[23] VardimanJW, ThieleJ, ArberDA, et al.. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood., 2009, 114(5): 937-951.

[24] HuangZ, YanH, TengY, ShiW, XiaL. Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia. Front Immunol., 2022, 131017850.

[25] ZhangR, LuX, TangLV, et al.. Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation. Front Immunol., 2022, 13. 993419

[26] ReshefR. Prevention of graft-versus-host disease. Clin Adv Hematol Oncol HO., 2012, 10(10): 663-665

[27] WangY, LiuQF, LinR, et al.. Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. Sci Bull., 2021, 66(24): 2498-2505.

[28] GabertJ, BeillardE, van der VeldenVHJ, et al.. Standardization and quality control studies of “real-time” quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia., 2003, 17(12): 2318-2357.

[29] StelljesM, KrugU, BeelenDW, et al.. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol Off J Am Soc Clin Oncol., 2014, 32(4): 288-296.

[30] Jongen-LavrencicM, GrobT, HanekampD, et al.. Molecular Minimal Residual Disease in Acute Myeloid Leukemia. N Engl J Med., 2018, 378(13): 1189-1199.

[31] GaidzikVI, WeberD, PaschkaP, et al.. DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. Leukemia., 2018, 32(1): 30-37.

[32] Rothenberg-ThurleyM, AmlerS, GoerlichD, et al.. Persistence of preleukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia., 2018, 32(7): 1598-1608.

[33] MoritaK, KantarjianHM, WangF, et al.. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol Off J Am Soc Clin Oncol., 2018, 36(18): 1788-1797.

[34] De BoerEN, JohanssonLF, De LangeK, et al.. Detection of Fusion Genes to Determine Minimal Residual Disease in Leukemia Using Next-Generation Sequencing. Clin Chem., 2020, 66(8): 1084-1092.

[35] PressRD, EickelbergG, FromanA, et al.. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse. Am J Hematol., 2019, 94(8): 902-912.

[36] BlomberyP, JonesK, DoigK, et al.. Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory. Arch Pathol Lab Med., 2018, 142(5): 606-612.

[37] LiuJ, WuD, LiuQ, et al.. More than two courses of pretransplant consolidation therapy benefits patients with acute myeloid leukemia in the first complete remission who underwent human leukocyte antigen-matched sibling allografts: a multicenter study. Chin Med J (Engl)., 2023, 136151855.

[38] BuccisanoF, MaurilloL, PiciocchiA, et al.. Pretransplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia. Bone Marrow Transplant., 2017, 52(3): 473-475.

[39] DebarriH, LebonD, RoumierC, et al.. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget., 2015, 6(39): 42345-42353.

[40] WangL, ShuM, ZhangZ, et al.. Prognostic impact of clonal hematopoiesis mutations at complete molecular remission in acute myeloid leukemia with NPM1 mutation. J Cancer Res Clin Oncol., 2024, 15010465.

[41] Zhang X hui, Chen J, Han MZ, et al. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol OncolJ Hematol Oncol. 2021;14:145.

[42] KiharaR, NagataY, KiyoiH, et al.. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia., 2014, 28(8): 1586-1595.

[43] RashidiA, HamadaniM, ZhangMJ, et al.. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv., 2019, 3(12): 1826-1836.

[44] LvM, ChangYJ, HuangXJ. Update of the “Beijing Protocol” haplo-identical hematopoietic stem cell transplantation. Bone Marrow Transplant., 2019, 54(Suppl 2): 703-707.

[45] ZhangR, ShiW, WangHF, et al.. Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia. Bone Marrow Transplant., 2017, 52(9): 1253-1260.

[46] ZhangR, LuX, WangH, et al.. Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant., 2019, 25(1): 47-55.

[47] FangJ, ZhangR, WangH, et al.. Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study. Leuk Res., 2016, 46: 61-68.

[48] HongM, WuQ, HuC, et al.. Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis. Bone Marrow Transplant., 2012, 47(2): 196-202.

[49] LiZ, ShiW, LuX, et al.. Decitabine-Intensified Modified Busulfan/Cyclophosphamide Conditioning Regimen Improves Survival in Acute Myeloid Leukemia Patients Undergoing Related Donor Hematopoietic Stem Cell Transplantation: A Propensity Score Matched Analysis. Front Oncol., 2022, 12. 844937

[50] LooS, DillonR, IveyA, et al.. Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome. Blood., 2022, 140(22): 2407-2411.

Funding

National Natural Science Foundation of China(81974003)

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to Huazhong University of Science and Technology